This clinical trial focuses on patients with Ulcerative Colitis, a chronic inflammatory condition affecting the large intestine. The study specifically targets individuals with moderately to severely active disease. The investigational medication being tested is RO7837195, which is a recombinant bispecific antibody given as a solution for injection under the skin (subcutaneous use).
The purpose of this study is to determine if RO7837195 is effective in inducing remission in people with moderately to severely active Ulcerative Colitis when compared to placebo. The study is designed as a double-blind trial, meaning neither the participants nor the doctors know who receives which treatment during the study. The medication will be tested over a 12-week period, followed by an additional treatment phase.
During the study, participants will receive either RO7837195 or placebo through injections under the skin. The study will monitor various aspects of the disease activity, including symptoms such as stool frequency and bleeding. The researchers will also track how the body processes the medication and check for any potential side effects throughout the study period.
Czechia 
France 
Germany 
Italy 
Poland 
